Gilead Sciences stock returns 11.61% annually over 20 years
Gilead Sciences has delivered an average annual return of 11.61% over the last 20 years, outpacing the market by 2.3% annually. With a current market cap of $155.75 billion, a $100 investment made two decades ago would now be worth $903.01.

*this image is generated using AI for illustrative purposes only.
Gilead Sciences has generated an average annual return of 11.61% over the past 20 years, outperforming the market by 2.3% on an annualized basis. The biopharmaceutical company currently holds a market capitalization of $155.75 billion. This long-term performance highlights the impact of compounded returns on investor wealth over extended periods.
Investment Growth Analysis
If an investor had purchased $100 worth of Gilead Sciences stock 20 years ago, that investment would be valued at $903.01 today. This calculation is based on the company's current share price of $125.45. The substantial growth underscores the potential benefits of long-term equity investments in established healthcare entities.
Key Performance Metrics
| Metric | Value |
|---|---|
| Average Annual Return | 11.61% |
| Market Outperformance vs Market | 2.3% |
| Current Market Capitalization | $155.75 billion |
| Current Share Price | $125.45 |
| 20-Year Growth on $100 Investment | $903.01 |
The data illustrates how consistent returns can significantly multiply initial capital over a 20-year horizon. Gilead Sciences' ability to deliver market-beating returns has resulted in nearly a nine-fold increase on a hypothetical investment made two decades ago.
Can Gilead Sciences sustain its historical 11.61% annual return given current patent cliffs and pipeline developments?
How will the company's $155.75 billion market cap limit its future growth potential compared to the last two decades?
What impact will recent shifts in healthcare policy and pricing regulations have on Gilead's future profitability?




























